Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-17T09:39:19.524Z Has data issue: false hasContentIssue false

CPE Colonization - Once A Carrier Always A Carrier? Response to Lewis and Bart

Published online by Cambridge University Press:  09 October 2015

Hilary Humphreys
Affiliation:
Department of Clinical Microbiology, the Royal College of Surgeons in Ireland, Dublin, Ireland Department of Microbiology, Beaumont Hospital, Dublin, Ireland.
Anna-Rose Prior
Affiliation:
Department of Clinical Microbiology, the Royal College of Surgeons in Ireland, Dublin, Ireland Department of Microbiology, Beaumont Hospital, Dublin, Ireland.
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

To the Editor—We read with interest the studies by Lewis et alReference Lewis, Enfield, Mathers, Giannetta and Sifri 1 and Bart et alReference Bart, Paul, Eluk, Geffen, Rabino and Hussein 2 on efforts to predict clearance of gastrointestinal colonization with carbapenemase-producing Enterobacteriaceae (CPE) based on follow-up rectal screens. The authors are to be congratulated for trying to address an important infection prevention issue, ie, whether there is a time when contact precautions, specifically isolation, can be discontinued. Both studies report that a significant proportion of patients who had negative CPE surveillance cultures following their initial positive screen remained colonized with CPE at follow-up screening: 13% (36 of 276) and 33% (7 of 31) in the studies by in the study by Bart et al and Lewis et al, respectively. Indeed, even after further screening, CPE was detected in 2 patients who had been found to be negative on 3 occasions following their initial positive screen.Reference Lewis, Enfield, Mathers, Giannetta and Sifri 1 It is also important to note that no single culture-based screening method routinely employed has the high level of sensitivity required to detect all genotypes of CPE, particularly those displaying low-level resistance.Reference Nordmann, Gniadkowski and Giske 3 Therefore, the rates of recurrent carriage may, in fact, be underestimated. Bart et al attempt to identify those risk factors that correlate with CPE recurrence. However, given the relatively small numbers of patients identified and the limitations of this study, further work is certainly needed in this area.

Recent guidelines on infection prevention and control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients highlight the dearth of good evidence and confirm that no consensus exists on when contact precautions may be discontinued.Reference Tacconelli, Cataldo and Dancer 4 Furthermore, it is mistaken to make assumptions based upon other multidrug-resistant organisms, specifically methicillin-resistant Staphylococcus aureus (MRSA), where recognized decolonization regimens are commonly used because such treatment often assists in shortening the duration of carriage. In addition, for MRSA, the major reservoir of colonization is the skin and nasal mucosa, whereas for CPE and vancomycin-resistant enterococci (VRE), the gastrointestinal tract is the important reservoir. Although guidelines suggest that 3 consecutive negative swabs may allow for discontinuation of contact precautions in patients with VRE, this may be difficult to achieve in practice given the gastrointestinal reservoir.Reference Siegel, Rhinehart and Jackson 5 In a study on a renal unit, 64% of patients remained positive for VRE when 3 or more follow-up rectal screening specimens were taken.Reference Humphreys, Dolan and Sexton 6 However, many of these were patients with chronic renal failure, which, in addition to other factors, may help explain this statistic. It is possible that, for groups with similar risk factors, the same difficulties arise with regard to persistent CPE carriage.

Much remains unknown about the natural epidemiology of patients with CPE and specifically when, and if, some patients ever lose the organism. Factors governing this condition are likely to be complex and include the underlying condition of the patient; the setting in which the patient is being cared for; recent, current, and the future administration of antibiotics and other drugs; and the complex milieu of the intestinal microbiome, which is dynamic and is likely to have an important impact on colonization. To date, we have largely relied on cultures to determine changes in the epidemiology of colonized patients with CPE, but the relationship between CPE and the remainder of the intestinal flora is likely to be complex. We need to apply meta-genomic approaches to explore that relationship and how it might affect the dynamic of CPE colonization.Reference Nami, Haghshenas and Abdullah 7 As our knowledge regarding possible exploitation and restoration of the intestinal microbiome develops, so too may our thinking regarding management of patients colonized with CPE.Reference Tosh and McDonald 8

Prospective studies using innovative laboratory techniques are needed on patients with CPE during outbreaks and in endemic settings over periods of time, while in the hospital and after discharge. These studies will help us further understand the natural history of CPE colonization and determine the host/patient, environmental, and microbial factors that may help us predict which patients remain transiently, intermittently, or permanently colonized. This work is required to scientifically inform infection prevention and control strategies on the use of contact precautions and to facilitate risk stratification of patients previously identified as CPE colonized. This research becomes increasingly important as the number of patients with CPE increases, especially in settings where single room/isolation facilities are limited.

ACKNOWLEDGMENTS

Financial support. No financial support was provided relevant to this article.

Potential conflicts of interest. HH receives research funding from Pfizer (Ireland) and has in recent years received lecture or consultancy fees from Pfizer and Cepheid.

References

REFERENCES

1. Lewis, JD, Enfield, KB, Mathers, AJ, Giannetta, ET, Sifri, CD. The limits of serial surveillance cultures in predicting clearance of colonization with carbapenamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 2015;36:835837.Google Scholar
2. Bart, Y, Paul, M, Eluk, O, Geffen, Y, Rabino, G, Hussein, K. Risk factors for recurrence of carbapenem-resistant enterobacteriaceae carriage: case-control study. Infect Control Hosp Epidemiol 2015;36:936941.Google Scholar
3. Nordmann, P, Gniadkowski, M, Giske, CG, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012;18:432438.Google Scholar
4. Tacconelli, E, Cataldo, MA, Dancer, SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalised patients. Clin Micro Infect 2014;20:S1S55.Google Scholar
5. Siegel, JD, Rhinehart, E, Jackson, M, et al. Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control 2007;35:S165S193.Google Scholar
6. Humphreys, H, Dolan, V, Sexton, T, et al. Implications of colonization of vancomycin-resistant enterococci (VRE) in renal dialysis patients. Learning to live with it? J Hosp Infect 2004;58:2833.Google Scholar
7. Nami, Y, Haghshenas, B, Abdullah, N, et al. Probiotics or antibiotics: future challenges in medicine. J Med Microbiol 2015;64:137146.Google Scholar
8. Tosh, PK, McDonald, LC. Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis 2012;54:707713.Google Scholar